Gareth J. Morgan¹, Matteo Ciuffreda², Isabella Spadoni³, Joseph DeGiovanni⁴

Congenital Heart Disease, Vol.13, No.3, pp. 458-462, 2018, DOI:10.1111/chd.12596

Abstract Aim: To assess the acute results of the first human use of the Optimus covered stent in complex coarctation of the aorta.
Methods and Results: We successfully implanted the Optimus covered stent in eight cases in patients whose preprocedural anatomy looked challenging for currently available covered stents. Six of the patients had native coarctation with one recoarctation following surgical repair. There were no significant complications with reduction in the mean invasive gradient from 22 to 1 mm Hg. The length of stents used ranged from 33 to 57 mm with a median shortening after expansion of 13%. Postprocedural follow-up with… More >

Georges Ephrem¹, Camden Hebson², Anitha John³, Estella Moore⁴, Maan Jokhadar⁴, Ryan Ford⁵, Gruschen Veldtman⁶, Yoav Dori⁷, Michelle Gurvitz^8,9, Brian Kogon¹⁰, Adrienne Kovacs¹¹, Meghan Roswick, Michael McConnell¹², Wendy M. Book⁴, Fred Rodriguez III^4,12

Congenital Heart Disease, Vol.14, No.2, pp. 128-137, 2019, DOI:10.1111/chd.12685

Abstract The initial “Frontiers in Fontan Failure” conference in 2015 in Atlanta, Georgia, provided an opportunity for experts in the field of pediatric cardiology and adult congenital heart disease to focus on the etiology, physiology, and potential interventions for patients with “Failing Fontan” physiology. Four types of “Fontan Failure” were described and then published by Dr Book et al. The acknowledgment that even Dr Fontan himself realized that the Fontan proce‐ dure “imposed a gradually declining functional capacity and premature late death after an initial period of often excellent palliation.” The purpose of the second “Frontiers in Fontan Failure” was to… More >

G.S. Kassab^1,*

Molecular & Cellular Biomechanics, Vol.16, Suppl.2, pp. 18-18, 2019, DOI:10.32604/mcb.2019.08416

Abstract In celebration of Dr. Fung’s 100 birthday, the presentation will focus on a biomechanical design-based approach to innovation of medical devices that addresses unmet clinical needs ranging from cardiovascular diseases (e.g., ischemic heart disease and heart failure) to obesity. The technologies attempt to restore biomechanical homeostasis through a minimally invasive (e.g., percutaneous or laproscopic) approach in time efficient and cost-effective manner. The illustratory technologies include: A) A catheter for selective retroperfusion and “arterialization” of coronary veins for myocardial revascularization; B) A suction-based catheter for ease of trans-septal access; and C) A laproscopic and reversible restrictive device for weight loss without… More >

Selma B. Jaconis^1,*, Augusto T. Morita², Paulo L. A. Coutinho³, Suzana Borschiver¹

Journal of Renewable Materials, Vol.7, No.11, pp. 1221-1230, 2019, DOI:10.32604/jrm.2019.00025

Abstract In recent years environmental and sustainability concerns have impacted the global chemical industry and instituted a rush to produce products from renewable raw materials. This dynamic, complex and turbulent organizational scenario, around themes touching on the issue of sustainable development model, was created involving a large number of different actors: chemical/petrochemical industries, agroindustry companies, oil/gas companies, brand owners and end users, biotechnology startups, governments, universities and society. This paper proposed the application of a structured and dynamic method of technological prediction for biopolymers in three levels: systematic monitoring process, relational database and the “alive” Technology Roadmapping visualization tool. The main… More >

Dalin Tang^1,2,*, Zhiyong Li¹

CMES-Computer Modeling in Engineering & Sciences, Vol.116, No.2, pp. 109-113, 2018, DOI:10.31614/cmes.2018.04201

Abstract This article has no abstract. More >

Chuanrong Wu^1,*, Veronika Lee¹, Mark E. McMurtrey²

CMC-Computers, Materials & Continua, Vol.60, No.1, pp. 365-378, 2019, DOI:10.32604/cmc.2019.06949

Abstract Product innovation is regarded as a primary means for enterprises to maintain their competitive advantage. Knowledge transfer is a major way that enterprises access knowledge from the external environment for new product innovation. Knowledge transfer may face the risk of infringement of the intellectual property rights of other enterprises and the termination of licensing agreements by the knowledge source. Enterprises must develop independent innovation knowledge at the same time they profit from knowledge transfers. Therefore, new product development by an enterprise usually consists of three types of new knowledge: big data knowledge transferred from big data knowledge providers, private knowledge… More >